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Abstract. Antibody-dependent cellular cytotoxicity 
(ADCC) is regarded as an important mechanism by which 
monoclonal antibodies (mAh) can exert an antitumour ef­
fect in vivo. It may be possible, therefore, to enhance the 
therapeutic efficacy of mAb by cytokines that are able to 
enhance the ADCC of human CD3-, CD56+, CD 16+ natu­
ral killer (NK) cells. We investigated in vitro the effects of 
recombinant interferon a  (rIFNa) and recombinant inter­
leukin 2 (rIL-2), alone or in combination, on the ADCC of 
human peripheral blood NK cells. Both cytokines en­
hanced the ADCC of the human effector cells. rIFNa in­
duced a maximally increased ADCC after an exposure of 
human effector cells to 20 IU/ml for 15-30 min, while 
rJL-2 induced optimal ADCC after incubation of the cells 
for 2 days in 20-50 U/ml. We now show that activation of 
the NK cells with a combination of rIL-2 and rIFNa in­
duced significantly higher levels of ADCC than either cy­
tokine alone. The highest ADCC was induced if the cells 
were first exposed to rIL-2 before rIFNa was added to the 
culture. Culture of NK cells in medium or rIL-2 decreased 
the expression of FcryRIII (CD16), indicating that intensity 
of CD 16 expression and level of ADCC are not directly 
correlated, although blocking experiments with a mAb 
directed against CD 16 showed that this FcyR was essential 
for ADCC of the human effector cells.
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Introduction
In the past decade immunotherapy trials with monoclonal 
antibodies (mAb) have been performed in patients with 
malignant disease and, although some impressive re­
sponses were observed that indicate the validity of the 
approach, the overall effects were limited [14]. The thera­
peutic efficacy of mAb, not coupled to toxins or radioiso­
topes, depends on the recruitment of host effector systems 
including complement, antibody-dependent cellular cyto­
toxicity (ADCC) and/or phagocytosis/cytostasis of anti­
body-coated tumour cells by cells of the reticulo-endothe- 
lial system.
The lymphokine interleukin-2 (IL-2), produced by acti­
vated T-helper cells, is an important regulatory lym­
phokine that affects many different cells of the immune 
system, including T and B lymphocytes, monocytes and 
natural killer (NK) cells (for review see [31]). Clinical 
trials have been performed in patients with malignant dis­
ease with recombinant IL-2 (rIL-2 [30]) alone or in combi­
nation with autologous lymphokine-activated killer (LAK) 
cells or tumour-infiltrating lymphocytes (TEL) [29]. Al­
though the overall clinical responses were again limited, 
some impressive tumour regressions were documented, 
which encourage further attempts to improve the efficacy 
of this form of therapy.
Interferons (IFN) are a family of related cytokines pro­
duced by a variety of haematopoietic and non-haemato- 
poietic cells, which were originally described as soluble 
factors that inhibit viral infection and replication [3]. Re-
FNoft, the most common subtype of IFNoc, has
been tested in clinical trials in patients with malignant
disease and favourable responses were documented. IFN0C2 
can enhance the cytolytic activity of human peripheral 
blood NK cells and modulate IL-2-dependent LAK cell 
generation [16, 17, 32, 35]. However, the anti-neoplastic 
effect in the clinical trials was most likely due to a direct 
anti-proliferative effect of IFNa.2 on the tumour cells.
In addition to activation of the antibody-independent 
cytotoxic activity of lymphocytes, both rEL-2 and natural 
IFNa and IFNy have been shown to enhance the ADCC of
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these effector cells [2, 16, 18, 24]. However, systematic 
kinetics and dose/response experiments dealing with this 
effect of rINFoc have so far not been published.
immunotherapy experiments with anti-idiotypic mAb 
in combination with rIL-2 or rIFNa, performed in a synge­
neic murine B lymphoma model, indicated that with these 
cytokines the therapeutic efficacy of the mAb could be 
significantly enhanced [4-6]. We have shown that a com­
bination of mAb (anti-CD19) therapy with rIL-2 synergis- 
tically enhances the antitumour activity against a Burkitt 
lymphoma transplanted in nude mice [36, 37]. These data 
indicate that in these murine models ADCC indeed is an 
important mechanism by which mAb mediate antitumour 
effects.
Since it is known that the most important ADCC effec­
tor cells in man are lymphocytes with the features of NK
munotherapy trials, the effects of the cytokines rIL-2 and 
rIFNa, alone or in combination, on the ADCC of human 
peripheral blood NK cells. Both cytokines enhanced the 
ADCC activity of the human effector cells, and activation 
with a combination of rIL-2 and rIFNa enhanced the 
ADCC to a significantly higher extent than each cytokine 
alone. Furthermore, we show that although the ADCC of 
the human effector cells was dependent on the function of 
the FcyRIII (CD 16), the level of ADCC was not correlated 
with the number of FcyRIII molecules expressed on the 
effector cells.
Materials and methods
Cell lines and cell culture conditions. The human cell lines used were 
Jiyoye, M14 and K562 (American Type Culture Collection, Rockville, 
USA). The cell lines were cultured in Dulbecco’s modified Eagle’s 
medium (DMEM) supplemented with 2 raM L-glutamine, non-essential 
amino acids, 100 IU penicillin/ml, 100 Jig kanamycin/ml and fetal calf 
serum (FCS, 10% v/v, PAA Laborgesellschaft, Austria).
Monoclonal antibodies. The mAb used in immunofluorescence experi­
ments and in cytotoxicity assays were: 32.2 (CD64) [21], CIKM5 
(CD32) [22], kindly provided by Dr. G. Pilkington, Melbourne, 
Australia; NKI-L15 (CDlla) [19], NKI-L16 (CDlla) [20], CLB LFA 
1/1 (CD 18) [23], CLB-FcRgran.l (CD16) [38] and F(ab)2 fragments of 
CLB-FcRgran.l, kindly provided by Dr. T. W. J. Huizinga, CLB, 
Amsterdam; and ATI (CD38) (A. Helcman, unpublished), 4F2 [15], T3b 
(CD3) [33], CD 14 (Beckton Dickinson, Mountain View, Calif., USA), 
Leu 19 (CD56), Beckton Dickinson) and R24.3 (rat IgG2b anti-HLA- 
cJass-IT) [36]. R24.3 mAb was produced and purified (>95% pure as 
determined by sodium dodecyl sulphate/polyacrylamide gel electro­
phoresis analysis) by Euroclone Bv, Amsterdam* The Netherlands.
Isolation and cytokine activation of the LL subpopulation of human PBL 
Peripheral blood lymphocytes (PBL) of healthy volunteers were frac­
tionated by means of centrifugal élutriation as described previously [12]. 
The large lymphocyte (LL) fraction was used in all our experiments. This 
LL fraction was enriched for CD3~, CD16+, CD56+ NK cells (25%—40% 
CD3~, 60% -75% CD3+) and contained no B lymphocytes and up to 5% 
monocytes. The isolated LL were washed once with DMEM/FCS and 
suspended in DMEM/FCS at (2-3) x  106 cells/ml. rIL-2 was a generous 
gift from Eurocems BV, Amsterdam [3] and rIFNcc (Roferon) was ob­
tained from Hoffrnann-La Roche BV, Mijdrecht, the Netherlands. The 
LL were activated by culturing at 37° C in humidified air containing 5% 
CO2 in medium supplemented with the indicated amounts of one or both 
of these cytokines [rIL-2 concentrations are given in Cetus U
(1 Cetus U = 6 IU) and rIFNa concentration in IU]. Activating the cells 
with a combination of both cytokines was performed without washing 
the cells to remove the cytokine to which the cells were exposed first. In 
order to remove the cytokine with which the LL were activated the cells 
were extensively washed with complete medium before being used in the 
cytotoxicity assay or for immunophenotyping.
Itnmunofluorescence. Cells were incubated in the appropriate dilution of 
mAb [(0.5 -1) x 105 cells in 25 pi] in V-bottom 96-well microtiter plates 
(Greiner). For the determination of background staining the cells were 
incubated with mAb K8, which reacts only with the idiotype of the 
tumour cells of a non-Hodgkin lymphoma patient [28]. Bound mouse Ig 
was detected with fluorescein-isothiocyanate (FITC)-conjugated F(ab)2 
fragments of goat anti-(mouse Ig) (GAM/FITC, Tago, Burlingame, 
Calif., USA). All incubations were performed for 30 min at 4° C and after 
each incubation the cells were washed once with 100 pi phosphate- 
buffered saline supplemented with 0.5% (w/v) bovine serum albumin 
and 0.02% (w/v) sodium azide. Fluorescent staining was analysed with a 
Facscan cytofluorometer (Becton Dickinson). Antigen density is ex­
pressed as the fluorescence index (FI) calculated on the basis of fluores­
cence intensity (mean channel number, nmc) according to the following 
formula:
/ime positive population with test mAb -  /zmc negative control
FX = ---------------------------------- ;---------------------------------------
nmc negative control
ADCC assay. ADCC was determined with short-term 51Cr-reIease ex­
periments [39]. All ADCC experiments were performed with the R24.3 
mAb, a rat IgG2b mAb, which detects a common epitope on HLA 
class n  molecules, and the class IF Burkitt cell line Jiyoye was used as a 
target. Non-activated and cytokine-activated LL were washed with me­
dium before they were mixed with 103 51Cr-labelled Jiyoye cells (label­
ling with 5ICr: MMBq/lO6 cells incubated at 37° C for 60-120 min, 
sp.act. slCr= 13-22 GBq/mg chromium; Amersham, Buckingham­
shire, England) at effector-to-target cell (E/T) ratios varying from 100:1 
to 0.3:1 in triplicate in the absence or presence of the indicated amounts 
of R24.3 mAb in 96-well round-bottom microtiter plates (Sterilin). The 
final volume was 200 pi. Subsequently the plates were centrifuged for
2 min at 1000 rpm and incubated for 4 h at 37“ C in humidified air 
containing 5% CO2. After this incubation period the plates were centri­
fuged again (2 min, 1000 rpm) and 100 pi supernatant was harvested and 
the 5lCr content was determined in a gamma counter (Packard). The 
percentage specific label release was calculated according to the follow­
ing formula:
Specific 51Cr release (%) = 100 x (TS)l(M-S)
where 51Cr (cpm) in test sample, M  = maximal releasable label in 2% 
(v/v) Triton X-100, 0.5% (w/v) sodium dodecyl sulphate, 1% (w/v) 
sodium deoxycholate and 10 mM EDTA, and S = spontaneously released 
label from target cells alone. The spontaneous label release never 
exceeded 15% of the maximal releasable radioactivity.
Calculation of cytotoxicity (lytic units) and statistical analysis. For calcu­
lating lytic units from 5lCr-release curves, the curves were fitted to the 
von Krogh model [51Cr release = A(l+/c/ET)“NJ [27] after a variance-sta- 
bilizing 2/3 power transformation using non-linear least-squares regres­
sion. Subsequently we tested whether all the curves obtained from one 
donor could be described using identical A and N  values; this is equiva­
lent to testing whether the only difference between the different curves 
from one donor is a parallel horizontal shift in a 51Cr-release versus log 
(ET) plot. If this assumption was not justified (.P <0.05), we tested 
whether at least the A or the N  values could be considered to be equal. If 
this also was not possible, for every different curve an individual N  and A 
value was determined. In all statistical comparisons of different curves 
the F-test was used. In this, the denominator was always based on all data 
form the donor, not just the curves to be compared. By doing this it was 
often possible to increase the degrees of freedom of the denominator of 
the F-test from 6 to 18.
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Fig. 1. Large lymphocytes (LL) were cultured for the indicated time in 
50IU recombinant interferon a (rIFNa)lm\. The results of two indepen­
dent experiments are shown. Cytotoxicity is expressed as LU ±  SE. Cy­
totoxicity in the absence of mAb was not more than 25% of the cytotox­
icity in the presence of R24.3 mAb. The LL fractions from donors 1 and 
2 contained 20% and 27% CD16+ cells respectively
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Fig. 2. The LL were activated for 15 min or 30 min with the indicated 
concentration of rIFNa. Cytotoxicity is expressed as LU±SE. The LL 
fraction from this donor contained 28% CD16+ cells
Table 1. Antibody-dependent cellular cytotoxicity (ADCC) of large lym­
phocytes (LL) activated with a combination of recombinant interIeukin-2 
(rIL-2) and recombinant interferon oc (rIFNa)®
Donor CD16+ Cytotoxicity (LU 30%/I06 effector cells)
(%) (SE, n = 6) after activation with
Medium rIL-2*1 rIFNa*2 rIL-2+rIFNa*3
1 38 212(20) 314 (23) 286 (23) 417 (30)
2 26 12(2) 25 (5) 32 (3) *4 85 (14)
3 21 12(3) 70(6) 15 (4)*4 192 (30)
4 32 446(74) 2236(510) 817 (153) 5734 (1609)
5 17 70 (8) 440(67) 323 (47) 1666 (322)
6 20 63(5) 239(13) 94 (6) 521 (30)
7 35 79 (13) 438 (76) 143 (23) 1816(565)
8 30 11(1) 47(7) 26(4) 103 (15)
9 21 9(2) 71(7) 28 (3) 102 (10)
10 19 30(3) 154(15) 74(7) 394 (40)
8 The F-test was used in all comparisons. LL were used immediately 
after isolation except for cells from donors 1, 2 and 4, which had been 
stored in liquid nitrogen before use. The LL were cultured overnight in 
medium or in medium supplemented with rIL-2 (50 U/ml; donor 4: 
25 U/ml). rIFNa (25 IU/ml) was added to the appropriate cultures for 
30 min. The cells were washed once and mixed with 103 51Cr-labelled 
Jiyoye target cells at six E/T ratios in the presence of R24.3 mAb 
(1 p,g/ml). Cytotoxicity is expressed as lytic units (30%)/106 effector 
cells (Llfcoa) and the SE is shown in parentheses. One lytic unit is 
defined as the number of effector cells needed to kill 30% of 103 target 
cells and was calculated as described in Materials and methods. Cytotox­
icity (LU) in the absence of mAb was not more than 15% of the value in 
the presence of mAb 
P ^0.02 versus medium 
*2 P ^0,03 versus medium, except *4 not significantly different versus 
medium
*3 P ^0.02 versus rIL-2 alone
Results
rIFNa or rIL-2 activation o f the ADCC ofLL
The LL obtained from 22 random donors were tested for 
cytotoxic activity after activation with rIFNa. In these
experiments we noted variability in the reaction of the LL 
to rIFNa stimulation. The LL of 4 out of these 22 donors 
did not respond with increased ADCC, while more than 
80% (18/22) did show increased ADCC after rIFNa acti­
vation compared to ADCC of LL cultured in medium. The 
kinetics of rIFNa activation of the ADCC of L fractions 
obtained from two random donors, tested in two separate 
experiments, is shown in Fig. 1. The antibody-independent 
activity of the LL from these donors was below the detec­
tion limit (<1 LU) and is therefore not indicated. Using the 
LL from donor 2 the largest gain in ADCC was seen after 
incubation for 15 min with 50 IU/ml, with some additional 
increase after 20 h of activation. Maximal ADCC of the LL 
from donor 1 was reached after 60 min exposure to this 
dose of rIFNa. Although, the LL from donor 1 (Fig. 1) 
needed a 60-min exposure to reach maximal ADCC, the 
results of other experiments showed that the minimal time 
needed to reach maximal ADCC with 50 IU rIFNoe/ml was 
15 min for LL obtained from most donors (see donor 2, 
Fig. 1).
In subsequent experiments the dose/response relation of 
rIFNa activation of LL was determined. The results of a 
representative experiment are shown in Fig. 2. Exposure of 
the LL from this donor to 20 IU rIFNa/ml for 15 or 30 min 
induced maximal ADCC. Other dose/response experi­
ments gave similar results, although the LL obtained from 
some donors needed a minimum of 50 IU rIFNa/ml for the 
induction of maximal ADCC.
In Table 1 the effect of IFNa and/or IL-2 activation on 
the ADCC of the LL of 10 healthy donors is shown. These 
results show that there is a considerable variation in the 
baseline level of ADCC and that LL from different donors 
react differently to activation with these cytokines. Despite 
this variability, however, the ADCC of LL obtained from 
all these donors significantly increased after exposure to 
rIL-2. The results of other experiments with rIL-2 alone 
(data not shown) showed that culture of LL from most 
donors for 2-3  days with 10-*50 U rIL-2/ml increased 
their ADCC to the maximal level, while for the induction 
of maximal anti body-independent cytotoxic activity more
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rIL-2 and/or a longer exposure time were needed. These 
results confirm data published by other investigators
[18, 24].
Activation o f LL with a combination o f rIL-2 and rIFNa
Since it is known that the induction of LAK cell activity 
with IL-2 can be modulated by a number of other cy­
tokines, including IFNa [17, 32, 35], we investigated the 
effect on ADCC of simultaneous activation of LL with 
rIL-2 and rIFNa. In initial experiments a number of varia­
bles were tested including time of rIL-2 activation and time 
of rIFNa addition. In some of these experiments the LL 
were activated for 3 days with rIL-2, and rIFNa was pre­
sent either during the entire activation time or only for the 
last few hours. The results of these experiments (data not 
shown) indicated that maximal effects were achieved by 
pre-activating the cells with rIL-2 prior to the addition of 
IFNa. Moreover, pre-activation of the cells with rIL-2 
followed by an exposure to rIFNa induced a significantly 
higher ADCC than either cytokine alone at the same dose 
levels and exposure times. Subsequently, the LL from ten 
different donors were tested using the same activation 
schedule (Table 1). As already stated above, the ADCC of 
LL cultured in medium alone was very variable. It is note­
worthy, however, that LL cultures from all 10 donors 
showed significantly higher ADCC after activation with 
rIL-2 and that 8/10 showed significantly higher ADCC 
after activation with rIFNa, although the effect of rIL-2 
was much more pronounced compared to the effect of 
rIFNa. Activation of the cells from all these donors with 
rIL-2 followed by a 30-min exposure to rIFNa significant­
ly increased the ADCC compared to the increase with 
rIL-2 alone (Table 1, P ^0.02). It is important to note that 
this was also the case with cells from the donors 2 and 3, 
who did not respond to rIFNa alone.
Phenotype of freshly isolated and cultured LL
In immunofluorescence experiments the phenotype of 
freshly isolated LL and LL cultured in medium, rIL-2 
and/or rIFNa was determined. It should be noted, however, 
that the cytotoxic activity was only determined for cells 
cultured in medium with or without rIL-2 and/or rIFNa 
Culture of the LL in medium alone or in medium with 
rIL-2 resulted in a decrease of the average FcyRIH (CD 16) 
expression per cell and also in very small decrease of the 
percentage of FcyRIII+ cells. One experiment is shown in 
Fig. 3. In the fresh LL, 39,5% of the cells were CD16+ with 
a fluorescence index (FI) of 74, while these parameters 
changed to 36,0% CD16"1-, FI = 29,7 for the cells cultured 
in medium and 34.7% CD164*, FI = 19.8 for the cells cul­
tured in rIL-2. Additional immunofluorescence experi­
ments showed that the decrease of CD16 expression was 
not reproducibly different between LL cultured in medium 
and LL cultured in rIL-2. Since culture of the LL with rIL-2 
consistently induced an increase of the ADCC activity and 
a decrease of the average CD16 expression, it can be con­
cluded that the level of ADCC is not correlated with the 
intensity of CD 16 expression.
In the immunofluorescence experiments a number of 
other cell-surface markers were also tested. No significant 
changes were observed in the expression of HLA class IT, 
CD3, CD32, CD64, CD18, and CDlla. The NK cell 
marker CD56 (Fig. 4), the cell-adhesion molecule ICAM-1 
and the activation markers CD38 and 4F2 increased after 
culture of the cells in rIL-2 (data not shown). The results of 
Figs. 3 and 4 also show that rIL-2 activation increased the 
expression of the 55-kDa chain of the IL-2 receptor 
(CD25) and of NKI-L16, an activation epitope on the leu- 
cocyte-function-associated antigen 1 (LFA-1) [13, 20],
LL activated with rIFNa were tested for the same 
markers as described above and only the expression of 
CD38, CD56, 4F2 and ICAM-1 increased. Incubation of
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Fig* 6. LL were activated for 16 h with 50 U rIL-2/ml and for the last 
30 min rIFNa was added to the appropriate cultures. Non-activated cells 
were cultured in medium alone. LL were mixed in vitro with 51 Cr- 
labelled Jiyoye target cells in the presence of the indicated amount of 
R24.3 mAb. Cytotoxicity is expressed as LU ±  SE
Fig. 5. Involvement of FcyRIH in the antibody-dependent cellular 
cytotoxicity of LL cultured for 2 days in medium (A) or medium supple­
mented with 25 U recombinant interleukin-2/ml (B). After activation 
the LL were washed with medium and mixed with SICr-labelled Jiyoye 
target cells at four E/T ratios in triplicate in the absence (control) or 
presence of R24.3 mAb (1 fxg/ml). CLB-FcRgran.l (anti-CD 16) mAb 
was added as ascites (1/500 final dilution) and F(ab>2 fragments 
(10 lig/ml). Cytotoxicity is expressed as percentage specific 51Cr re­
lease ±  SD (n = 3)
LL with a combination of rIL-2 and rIFNa, according to 
the same schedule as used in the experiments shown in 
Table 1, did not show a qualitatively different change in 
phenotype from that induced by either cytokine alone, al­
though the increase in expression of CD56 and CD54 was 
more pronounced (data not shown).
Involvement of FcyRIII (CD 16) in the ADCC of LL
To test whether the FcyRIII (CD 16) on the human effector 
cells was involved in the ADCC activity of LL, blocking 
experiments were performed with the anti-FcyRHl mAb 
CLB-FcRgran.l. This mAb is known to inhibit FcyRIII- 
mediated functions of granulocytes and monocytes [38]. In 
Fig. 5 a representative experiment is shown in which the 
anti-FcyRHI mAb was added to the cytotoxicity assay. The 
ADCC activity of the LL was completely blocked by CLB- 
FcRgran.l mAb to the level of cytotoxicity observed in the 
absence of R24.3 mAb. This inHbition was observed with 
intact CD 16 mAb (ascites) as well as with F(ab)2 frag­
ments. It is significant that the enhanced ADCC of LL 
activated with rEL-2 was also completely blocked with 
CLB-FcRgran. 1 (Fig. 5 B) suggesting that it is unlikely that
other yet undefined FcyR species are involved in the effect 
of rIL-2 on the ADCC of LL.
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Monoclonal antibody dose/response relationship
mAb titration experiments were performed to test whether 
the activation of LL with rIL-2 and/or rIFNa influenced 
the concentration of R24.3 mAb needed to induce ADCC. 
In Fig. 6 the results of one of these experiments are shown. 
Cytokine activation of LL did not decrease the minimal 
concentration of mAb (50 ng/ml) nor did it affect the op­
timum concentration of mAb (1000 ng/ml) that was 
needed for the induction of ADCC. The consistent effect of 
rIL-2 and/or rIFNa activation was that the cytotoxic activ­
ity at a given mAb concentration increased.
Discussion
In this paper we confirm other reports that show that the 
cytokines IL-2 and IFNa can enhance the ADCC of human 
peripheral blood lymphocytes [2, 18, 24, 16]. We show 
here that activation of PBL with a combination of rIL-2 and 
rIFNa enhanced the ADCC activity of these effector cells 
to a significantly higher extent than either cytokine alone.
Experiments performed to determine optimal condi­
tions for the enhancement of the ADCC of LL with rIFNa 
showed that maximal ADCC was reached with doses of 
rIFNa between 20 and 50 IU/ml and that the LL had to be 
exposed for 15-30 min to rIFNa (Figs. 1 and 2). These 
conditions also induced optimal antibody-independent ac­
tivity although the level of this activity induced by rIFNa 
was rather moderate and for some LL populations even 
below the detection limit of the 51Cr-release assay 
(<1 LU). In contrast to the results with rIFNa, rDL-2 in­
duced maximal ADCC at lower doses of rIL-2 and shorter 
exposure times in comparison with the conditions needed 
to induce maximal antibody-independent activity (data not 
shown [18,24]).
The cytotoxicity data with rIL-2 and/or rEFNa-activated 
LL from random healthy donors showed that baseline anti­
body-dependent and antibody-independent cellular cyto­
toxicity was variable (illustrated in Table 1 with the LL 
from ten random donors). This variable baseline activity, 
however, did not preclude an enhancement of ADCC after 
rIL-2 and/or rIFNa activation. The LL of all donors shown 
in Table 1 responded to rIL-2 with significantly enhanced 
ADCC and eight of the donors did show enhanced ADCC 
after activation with rIFNa. Prior activation with rIL-2 
resulted in a further increase in ADCC after exposure to 
rIFNa. It is notable also that the LL that did not react to 
rIFNa alone did respond after prior activation with rIL-2. 
This suggests that the activation state of the LL may deter­
mine whether or not they respond to rIFNa. On cells from 
IFNa-non-responsive donors, rIL-2 may induce receptors 
for IFNa [8].
A negative effect of rIFNa on LAK cell induction by 
IL-2 has been found by several investigators [32, 35], 
However, one of these studies [35] also shows that expo­
sure to rIFNa for 1 h enhanced the LAK activity of PBL 
pre-activated with rIL-2 for 4 days. In our experiments we 
also noticed that the time of addition of rIFNa was critical.
Our mAb dose/response relationship experiments 
(Fig. 6) confirm data published by Munn et aL [24] and 
show that rIL-2 and/or rIFNa activation increases the level 
of killing at a given mAb dose but does not reduce the 
minimal dose of mAb needed for ADCC,
Inhibition experiments performed with the mAb CLB- 
FcRgran.l (Fig. 5) showed that the ADCC activity of LL 
cultured in medium or rIL-2 was mediated by the FcyRHI 
(CD16) recognized by this mAb. Surprisingly, culture of 
LL decreased the CD16 expression per cell (Fig. 4). These 
results indicate that, in contrast to the enhancement of the 
ADCC activity of murine lymphocytes by rIL-2, which has 
been suggested to be associated with an increase in the 
number of FcyRH+ cells [10], the mechanism of IL-2 en­
hancement of the ADCC of human lymphocytes is not an 
increase in the expression of FCyRIII or the induction of 
yet undefined FcyR species.
Nagler et al. [25] published data indicating that the 
CD 16 expression on human peripheral blood NK cells is 
heterogeneous. They were able to discriminate three dis­
tinct CD3-negative NK cell subsets based on CD 16 expres­
sion; CD16neg., CD 16dim and CD16bright cells. They 
showed that the CD16dim subset was as efficient in lysing 
anti-CD 16-producing hybridomas as the CD16bri2ht subset, 
suggesting that the CD16dim subset expresses sufficient 
CD16 molecules per cell to mediate ADCC. Furthermore, 
they showed that the CD16nes and 0016^™ subsets pro­
liferate more efficiently than the CD16bright subset in re- 
sponse to low doses of rJL-2. This suggests that the reduc­
tion of CD16 expression we observed as a result of culture 
may be caused by the enhanced proliferation of the 
CD16nes and/or C D ^ ^ 111 subsets, thereby increasing their 
relative contribution to the cell population resulting in a 
decreased average CD 16 expression.
A prominent effect of rIL-2 activation of the LL was the 
induction of the NKI-L16 determinant on he CD11 a mole­
cule, The anti-LFA-1 mAb NKI-L16 was shown pre­
viously to enhance LFA-1-mediated cell-cell interactions 
and the epitope recognized by this mAb is suggested to be 
expressed on activated forms of the LFA-1 molecule [20, 
13]. This effect of rIL-2 suggests that activated LL may 
adhere more efficiently to target cells expressing ICAM- 
l/ICAM-2 thereby increasing their efficiency in killing 
these targets. The results of preliminary cluster experi­
ments indeed show that activation with rIL-2 increased the 
adhesion of LL to Jiyoye target cells (data not shown). 
However, whether this enhanced adherence of effector 
cells to target cells is involved in the increased ADCC 
remains to be elucidated.
Our in vitro experiments suggest that the therapeutic 
efficacy of mAb may be enhanced by combination treat­
ment of mAb with rEL-2 and rIFNa. Eisenthal et al. [11] 
showed that treatment of the murine B16 melanoma with 
rIL-2, rIFNa and mAb resulted in an antitumour effect on 
macrometastases that were resistant to treatment with rIL-2 
and mAb alone.
In the experiments described in this paper we used a 
mAb that recognizes HLA class II antigens and this mAb
169
probably cannot be used in humans. However, a number of 
mAb of more relevant specificity have been described that 
indeed are able to mediate ADCC with human effector 
cells like the LYM-1 [7] and the CAMPATH-1 mAb [9].
The results of a clinical trial with long-term rEFNa 
treatment show that the treatment regimen employed 
caused a marked inhibition of B cell, T cell and NK cell 
function [34], again suggesting that rIFNa has differential 
effects, which are determined by the exposure times and 
the doses used.
The results presented in this paper indicate that clinical 
trials should be considered with mAb in combination with 
the cytokines rIL-2 and rIFNa. If in the treatment protocols 
the results of our in vitro experiments and those of other 
investigators in vivo are carefully considered, treatment 
with combinations of mAb, rIL-2 and rIFNa may be more 
effective than treatment with mAb and either cytokine 
alone.
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